Cancer cell membranes and associated entry receptors

Cancer cell membranes and associated entry receptors represent a critical interface for targeted oncology therapeutics, encompassing the unique lipid and protein composition of the malignant cell surface. These membranes often overexpress specific receptors—such as the transferrin receptor, folate receptor, and various integrins—which serve as 'entry ports' for targeted drugs, toxins, and oncolytic viruses through receptor-mediated endocytosis or membrane fusion [3.1.1, 3.1.5]. Additionally, the cancer cell membrane itself is characterized by alterations like phosphatidylserine exposure and increased fluidity, which can be exploited by membranolytic agents or biomimetic nanoparticles [3.3.2, 3.3.3]. By targeting these surface features, therapies can achieve enhanced selectivity, overcoming biological barriers and minimizing systemic toxicity compared to conventional treatments [3.3.1, 3.3.4]. However, the high degree of intratumoral heterogeneity and the presence of these receptors on some healthy tissues remain significant challenges for clinical efficacy and safety [3.1.5, 3.3.2]. This target class is central to the development of antibody-drug conjugates, oncolytic virotherapy, and membrane-coated nanomedicines [3.1.4, 3.3.5].

Other names

Tumor cell membranesCancer cell surface receptorsOncogenic entry portalsCancer cell membrane-associated receptors

Drugs and delivery systems interact with specific surface receptors or the lipid bilayer to facilitate cellular entry via receptor-mediated endocytosis, membrane fusion, or direct permeabilization, often exploiting the overexpression of these components in malignant cells [3.1.1, 3.3.1].